These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Constitutional jurisdiction over health in Canada. Jackman M Health Law J; 2000; 8():95-117. PubMed ID: 11398225 [No Abstract] [Full Text] [Related]
5. Department's role to administer health services. N Z Hosp; 1978 Jun; 30(5):13. PubMed ID: 10307746 [No Abstract] [Full Text] [Related]
6. The Canadian experience. Interview by Lyndon Keene. Labelle H N Z Nurs J; 1987 Mar; 80(3):10-2. PubMed ID: 3470682 [No Abstract] [Full Text] [Related]
7. Medical savings accounts and the Canada Health Act: complimentary or contradictory. Byrne JM; Rathwell T Health Policy; 2005 Jun; 72(3):367-79. PubMed ID: 15862644 [TBL] [Abstract][Full Text] [Related]
8. Restructuring of the Chronic Disease Program at the Laboratory Centre for Disease Control. Wigle DT; McCourt C; Li F Chronic Dis Can; 1996; 17(2):74-6. PubMed ID: 9079354 [No Abstract] [Full Text] [Related]
9. User fees if necessary but not necessarily user fees: CFPC. Rich P CMAJ; 2001 Nov; 165(11):1526. PubMed ID: 11762584 [No Abstract] [Full Text] [Related]
11. A national drug agency. West R; Borden EK; Collet JP; Rawson NS; Tonks RS CMAJ; 2003 Apr; 168(8):962-3. PubMed ID: 12695372 [No Abstract] [Full Text] [Related]
12. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study. Lexchin J Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811 [TBL] [Abstract][Full Text] [Related]
13. Rethinking for today or rethinking for tomorrow? Preparing medicare for the future. Lomas J Healthc Pap; 2000; 1(3):32-40; discussion 88-91. PubMed ID: 12811189 [No Abstract] [Full Text] [Related]
14. The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care. Begg E; Sidwell A; Gardiner S; Nicholls G; Scott R N Z Med J; 2003 Mar; 116(1170):U360. PubMed ID: 12658318 [No Abstract] [Full Text] [Related]
15. PHARMAC measures savings elsewhere to the health sector. Metcalfe S; Dougherty S; Brougham M; Moodie P N Z Med J; 2003 Mar; 116(1170):U362. PubMed ID: 12658320 [No Abstract] [Full Text] [Related]
16. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response. Adams J N Z Bioeth J; 2003 Oct; 4(3):22-3. PubMed ID: 15597478 [No Abstract] [Full Text] [Related]
17. CMA urges national equivalent of medicare for extended health services. Kondro W CMAJ; 2007 Sep; 177(6):558-9. PubMed ID: 17711930 [No Abstract] [Full Text] [Related]
18. Is a minority government in the offing? Might it be good for health care? Gray C CMAJ; 2000 Oct; 163(9):1180. PubMed ID: 11079067 [No Abstract] [Full Text] [Related]
19. Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders? MacKay P N Z Med J; 2005 May; 118(1214):U1433. PubMed ID: 15886729 [No Abstract] [Full Text] [Related]
20. Can the Senate save medicare? Gray C CMAJ; 2000 Apr; 162(8):1201. PubMed ID: 10789646 [No Abstract] [Full Text] [Related] [Next] [New Search]